Haemonetics Corporation has completed its acquisition of Vivasure Medical Limited, a Galway‑based developer of fully absorbable vascular closure devices. The transaction is valued at up to €185 million (about $215 million), consisting of an upfront cash payment of €100 million and up to €85 million in contingent consideration tied to sales milestones. Haemonetics financed the deal entirely from its cash reserves.
The acquisition adds Vivasure’s PerQseal Elite system—a sutureless, fully bio‑resorbable patch for large‑bore arterial and venous access—to Haemonetics’ Interventional Technologies portfolio. The technology complements the company’s existing hemostasis and closure products and positions Haemonetics to capture a growing share of the large‑bore closure market, which is expanding alongside structural heart and endovascular procedures.
PerQseal Elite has received CE Mark approval for both arterial and venous indications in Europe and a U.S. FDA PMA application was submitted in 2025. The regulatory approvals give Haemonetics a ready‑to‑market product in a segment that is experiencing increasing demand for minimally invasive vascular solutions, thereby accelerating the company’s global commercialization plans.
Haemonetics reported Q2 fiscal 2026 revenue of $327.32 million, up 1.6% from $321 million in the prior quarter, and an adjusted EPS of $1.27, beating consensus of $1.12 by $0.15. The earnings beat was driven by strong demand in core segments and effective cost control, while modest revenue growth reflected a mix shift toward higher‑margin products. The company’s gross margin of 58.26% and net margin of 12.67% underscore its healthy profitability profile.
Ken Crowley, VP & General Manager of Interventional Technologies, said the acquisition “expands Haemonetics’ complete range of closure devices with new and clinically differentiated technology to bolster our presence in the large‑bore closure market and our impact in fast‑growing structural heart and endovascular procedures.” Andrew Glass, CEO of Vivasure, noted that joining Haemonetics would accelerate the global availability of PerQseal Elite. Haemonetics plans to integrate Vivasure’s European manufacturing footprint to enhance its global reach.
Analysts highlighted the acquisition as a strategic fit that strengthens Haemonetics’ position in high‑growth vascular closure markets. The deal is viewed as a positive step toward diversifying the company’s product mix and mitigating headwinds in its Interventional Technologies segment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.